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ABSTRACT 
 
Background: Recurrent aphthous stomatitis is among the most common oral lesions 
observed by physicians. Definitive treatment has been difficult considering its unknown 
etiology; however, proposed immunologic factors have led to the use of 
immunosuppressive agents. Colchicine has been shown to have an effect on all types 
of RAS through its anti-inflammatory action by way of suppressing phagocytosis and 
migration of leukocytes, but its safety and efficacy have only been addressed in a few 
small studies.  
 
Method: An exhaustive search of available medical literature was conducted, from 2000 
to present, using CINHAL, Cochrane Systematic Reviews, PubMed, Medline-OVID, and 
MD Consult database. Quality of evidence in each article was assessed using GRADE. 
 
Results: Three studies met criteria for this systematic review. A double blind, 
randomized-controlled trial, demonstrated reduction in pain and burning sensation from 
baseline score ± SD in colchicine (7.92 ± 2.39 score, p<0.001) and number of aphthous 
ulcers (2.77 ± 1.49, p<0.001).  An open-label trial demonstrated excellent response to 
colchicine in 40% of ten patients, and moderate response in 50%. A retrospective study 
demonstrated 60% excellent therapeutic success in 50 patients using colchicine. 
 
Conclusion:  Based on this systematic review of literature and use of GRADE, there is 
moderate evidence showing colchicine is a safe and effective treatment in pain 
reduction and relapse prevention for patients with recurrent aphthous stomatitis. 
However, further research is likely to have an impact on estimate of benefit and risk. 
 
Keywords:  Colchicine, recurrent aphthous stomatitis. 
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INTRODUCTION 
Background 
 Recurrent Aphthous Stomatitis (RAS) is a pathologic condition characterized by 
recurring, painful, ulcers of the oral mucosa with outbreaks occurring three to four times 
per year or continuously. It is the most common cause of oral ulcers observed by 
physicians, affecting 20% of the US population and 2-66% of the international 
population (Axéll & Henricsson, 1985). It is a rather common affliction during childhood 
and adolescence, with a higher occurrence in females. (Crivelli, Aguas, Alder, 
Quarracino, & Bazerque, 1988). The three clinical presentations of RAS comprise of, 
minor, major and herpetiform. 
A disorder of uncertain etiology, various local, systemic, immunologic, nutritional, 
and genetic factors have been proposed for RAS. Irregularity in cellular immunity has 
been shown to play the main role in its pathogenesis Pakfetrat et al. (2010). It can also 
be associated with systemic diseases such as Behcet’s syndrome, systemic lupus 
erythematosus, Crohn’s disease, celiac disease, and ulcerative colitis (Crispian, Gorsky, 
& Lazada-Nur, 2003). 
Current systemic therapies in the treatment of RAS include diverse agents, 
including corticosteroids, pentoxifylline, dapsone, and more recently thalidomide. All of 
these current therapies, however, have varying degrees of effectiveness and have the 
potential for serious adverse effects. These factors exhibit the need for an improved 
treatment option of RAS. 
In the past two decades, the plant alkaloid colchicine has been shown to have a 
positive effect on all types of RAS due to its anti-inflammatory actions (Altenburg, Abdel-
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Naser, Seeber, Abdallah, & Zouboulis, 2007). These actions are caused by colchicine’s 
binding to microtubular protein, which suppress the mobility of granulocytes and 
phagocytosis of leukocytes Altenburg et al. (2007). The most common side effects 
occurring with the use of colchicine include nausea, vomiting, diarrhea and in rare cases 
of long-term use, myopathy, neutropenia, and aplastic anemia (Finkel, Cubeddu, & 
Clark, 2009). These recent discoveries have drawn increased interest in colchicine as a 
safe and effective treatment for patients with RAS. 
Purpose of the Study 
The purpose of this paper is to perform a systematic review of literature on the 
treatment of recurrent aphthous stomatitis with colchicine in comparison to other 
systemic therapies with regard to clinical response and side effects. Review of each 
article was done using the Grading of Recommendations Assessment, Development 
and Evaluation (GRADE) tool developed by the GRADE Working Group. Accordingly, 
the clinical question asks: In adult patients with recurrent aphthous stomatitis, is 
colchicine safe and effective in pain reduction and relapse prevention? 
 
METHOD 
 
Using the search terms “colchicine”, “aphthous stomatitis”, and “treatment”, an 
exhaustive literature search was performed using the following databases: CINHAL, 
Cochrane Systematic Reviews, PubMed, Medline-OVID, and MD Consult. These 
databases were accessed through the Pacific University Library system. Only articles in 
English were considered. The initial results included nine articles. Articles older than the 
year 2000 were excluded. This resulted in three studies to review and use in the final 
analysis. 
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RESULTS 
Comparison of Colchicine Versus Prednisolone in Recurrent Apthous Stomatitis: 
A Double-Blind Randomized Clinical Trial by Pakfetrat et al. (2010) 
The first study reviewed compared the therapeutic effects of prednisolone to 
colchicine in the treatment of RAS. In this randomized double blind clinical trial, 34 
patients with frequent RAS (at least three episodes each month), were unresponsive to 
conventional topical treatments, and had not taken any medication for treatment of RAS 
in two weeks prior to beginning the study, were included in the study.  Inclusion criteria 
was restricted to patients 18 years of age or older, who had normal results of biological 
screening (cell blood count, fasting plasma glucose, hepatic transaminases, serum 
levels of ferritin, iron, zinc, vitamin B12, B6, and folate). Subjects were excluded if they 
had previous medical history of systemic disease (diabetes mellitus, liver disease, 
inflammatory bowel disease, renal insufficiency, and Behcet’s disease), or who had 
taken any medicine that might have an effect on the immune system. 
Patients were randomly divided into two treatment groups with a daily dose of 
5mg/d prednisolone or 0.5 mg/d colchicine. Both groups took the medicine for three 
months. To guarantee blinding, a random number was generated for each participant 
using the Statistical Package for the Social Sciences (SPSS) software, after which, 
patients were referred to the pharmacist to obtain their assigned medication according 
to their number. Patients were instructed to report immediately any side effects at any 
time of the study until six months after treatment. Clinical findings of both study groups 
were evaluated every two weeks. Researchers assessed number of lesions, recurrence, 
intensity of pain (on a scale of 1-10 using visual analogue scale), and any side effects. 
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The mean age of the patients was 31.5 ± 11.9 years. Baseline characteristics of 
patients were as follows, pain and burning sensation (33.11 ± 11.83 for colchicine group 
and 29.82 ± 12.09; p=0.428 for the prednisolone group), and number of aphthous ulcers 
per case (3.06 ± 1.39 for colchicine group and 4.18 ± 2.16 for prednisolone group). 
After three months follow up, no significant differences were found between the 
two groups in regard to degree of pain (p=0.209), and number of aphthous ulcers per 
patient (p=0.673). Both groups showed a significant reduction in pain and burning 
sensation (7.92 ± 2.39, p<0.001 for colchicine and 8.21 ± 2.01, p<0.001 for 
prednisolone group) and number of aphthous ulcers (2.77 ± 1.49, p<0.001 for colchicine 
and 3.79 ± 2.49, p<0.001 for prednisolone group). During the follow up period, 9.1% of 
the patients displayed no recurrences, while in 36.4% of the patients a one-time 
recurrence was seen, and in 45.5% of the patients two recurrences were seen. Number 
of recurrences (p=0.171) and the duration of pain-free periods (p= 0.571) were not 
significantly different between the two groups. 
 In the study, 67.6% of the patients showed no side effects. Side effects of the 
colchicine (52.9%) group were significantly higher compared to the prednisolone 
(11.8%) group (p=0.027). These side effects included gastric disorders (n=8, 47.1%), 
head-ache (n=1, 5.9%), and vertigo (n=3, 17.6%). 
 The authors concluded that that both colchicine and prednisolone were equally 
effective in reducing pain, recurrences, and number of lesions in patients with RAS. Due 
to the higher incidence of side effects in colchicine, they preferred the use of 
prednisolone for patients with RAS. 
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Systematic Treatment in Severe Cases of Recurrent Aphthous Stomatitis: An Open 
Trial by (Mimura, Hirota, Sugaya, Sanches, & Migliari, 2009) 
The second study reviewed was an open-label, four-year clinical trial of twenty 
one consecutive patients with severe RAS, to evaluate the efficacy of the systemic 
drugs thalidomide, dapsone, colchicine, and pentoxifylline in the treatment of severe 
RAS. Patients were selected for the study based on a severe clinical course of RAS, 
such as multiple episodes of lesions monthly. Patients were excluded if they had any 
hematologic disease, Behcet’s syndrome, Crohn’s disease, HIV infection or Reiter’s 
syndrome, either initially or as a later development. Thirty-two patients were originally 
enrolled in the study after diagnosis of RAS, of which five participants were found to 
have the aforementioned systemic diseases and were excluded from the study. Twenty-
seven patients were enrolled in the treatment protocol. 
 Before entering the study, patients were informed of the medications and their 
possible side effects. A clinical history was recorded concerning the aphthae type, size, 
number, recurrence, healing time, and symptoms. Initially, patients were given 
0.5mg/kg/day of prednisone for a two-week period, decreased to half the initial dose 
after one week. Simultaneously, one of the four test drugs was assigned to each patient 
without blinding, keeping the proportion of assignments as equal as possible. After 
withdrawing the prednisone, the assigned drug was maintained for six months, unless 
adverse side effects or unsatisfactory results occurred. In either of these cases, the 
patient was switched to one of the other three drugs. Dosages given were, 100mg/ day 
of thalidomide, 25mg/day of dapsone that was increased 25mg every three days until 
100mg/day maintenance dose, 0.5mg/d of colchicine that was increased 0.5mg every 
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seven days until 1.5mg/day maintenance dose, and 400mg three times a day of 
pentoxifylline.  
In the study, patients were evaluated at fifteen day intervals, during which clinical 
status (benefits and side effects) was recorded, as well as compliance. Efficacy of each 
drug was determined by its potential to prevent relapse and/or reduce symptoms, 
number of ulcers, and healing time. Efficacy was classified as excellent (no relapses), 
moderate (patient showing relapses but with decreasing frequency, less lesions per 
cycle, and alleviated symptoms), mild (relief of symptoms only), or no response. 
Patients were followed for a period ranging from six to twelve months. 
Of the twenty seven patients, six stopped showing up for treatment, and data for 
these patients was omitted. The study was effectively conducted in twenty one (n=21) 
patients with a mean age of 35.5 years. Eleven patients were switched to alternative 
drugs during the study.  
Colchicine was administered to a total of ten patients for a time period of two to 
six months and resulted in four patients (40%) with excellent results showing complete 
remission, five patients (50%) with moderate to mild results showing relief of symptoms, 
and one patient (10%) with no response to treatment. Side effects of diarrhea occurred 
in three patients (30%), which improved after dosage adjustment. 
In conclusion, authors specified that significant relief occurred with most drugs, 
but relapse eventuated in all patients after medication was discontinued. They also 
determined that thalidomide provided the best results in the trial, although, the drug has 
problems in regard to accessibility and is highly contraindicated in fertile women. 
Colchicine demonstrated good results and was well tolerated by patients. 
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Successful Treatment of Complex Aphthosis with Colchicine and Dapsone 
by Lynde and Rogers III (2009) 
The final article reviewed was a retrospective study of 55 subjects with complex 
aphthosis, collected from medical records at the Department of Dermatology, Mayo 
Clinic, between the years 1998 and 2007 to investigate the effectiveness of colchicine 
and dapsone in the treatment of complex aphthosis. The study included only patients 
who received colchicine, dapsone, or both, and were available for follow-up. 
Patients included in the study received treatment according to a therapeutic 
ladder with colchicine being the initial drug. Dapsone was added for those who did not 
have a substantial response to colchicine (>75% improvement of symptoms) at twelve 
weeks, or who could not continue due to adverse effects.  
Colchicine was initiated at 0.6mg each evening for one week. If there were no 
gastrointestinal symptoms, the dose was increased to 1.2mg in the evening. Again, if 
the dose was tolerated, it was increased to 1.8mg. Dapsone was administered in a 
stepwise manner with the initial dose started at 25mg daily for 3 days and increased 
25mg every 3 days until 125-150mg was achieved. Patients were evaluated objectively 
and subjectively according to the frequency, intensity, and severity of aphthosis events.  
All patients included in this study had tried multiple topical therapies, and short 
course corticosteroids, resulting in failure. Colchicine was initially started in 52 of the 55 
patients (95%), two of which received dapsone simultaneously due to severity of 
disease, and had treatment success. Of the 50 patients who received colchicine alone, 
30 (60%) achieved therapeutic success and no longer needed further treatment. In this 
subset of patients with success, 29 (97%) had at least 75% improvement, and one 
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patient (3%) had complete resolution of symptoms. Of the 50 patients initially receiving 
colchicine alone, thirteen (26%) had no response to the medication and seven (14%) 
had adverse effects leading to their discontinuation of therapy. The most common 
adverse effect with colchicine was diarrhea (31%; 16 of 52), causing four (8%) to stop 
therapy. Other adverse effects occurred in five patients. These included a burning 
sensation in the feet and transient thrombocytopenia, which did not require therapy 
discontinuation, although occurrence of rash with elevated liver enzyme levels, easy 
bruising, and vomiting required discontinuation. 
The authors determined that these results offer promise for colchicine as an 
effective first-line non-steroidal therapy for complex aphthosis, concluding that 
colchicine therapy can be maintained long-term since it is safe and well tolerated with 
regular follow-up and monitoring. 
DISCUSSION 
 Treatment of RAS has proven to be difficult considering its unknown etiology, but 
over the years several factors have been proposed in which therapy has been directed.  
Colchicine, along with other systemic medications, has been used in attempt to relieve 
pain and prevent relapse, yet remain safe to the patient. The key points to discuss in 
this section are the general safety and efficacy of colchicine in the treatment of RAS, 
and the overall strength and limitations of the literature reviewed. 
All three studies reviewed found colchicine to be effective in the treatment of 
RAS in regards to the clinical outcomes of pain reduction, aphthae size and number, 
and prevention of relapse. Pakfetrat et al. (2010) demonstrated colchicine’s 
effectiveness, in comparison to prednisolone, in pain reduction, number and size of 
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aphthae, and recurrence of RAS. Patients in the colchicine group exhibited significant 
pain reduction by more than 85% during the twelve week period of therapy. Pain 
reduced rapidly in the first two weeks, then gradually thereafter. During follow-up, 
relapse did occur once in 41% of the patients and twice in 59% of the patients, which 
was similar to the prednisolone group.  
There were no serious adverse reactions in the colchicine group. The most 
common side effect was mainly gastrointestinal, occurring in less than 50% of the 
patients. The authors concluded that prednisolone and colchicine were nearly identical 
in results, but since more side effects occurred with the colchicine group they 
considered prednisolone the better choice. However, the long-term effects of 
prednisolone were not taken into consideration in the discussion of this study. 
Limitations found in the study were the relatively small sample size, determined 
appropriate via SPSS software before conducting the study, although, it necessitates 
caution when interpreting results. Also, the study was a retrospective in design and 
conducted in Iran, which may indicate a different effect of colchicine to that particular 
population, thus decreasing its external validity.  
The study conducted by Mimura et al. (2009) showed colchicine effectively 
decreased pain in 90% of the patients to whom it was administered during a period of 
two to six months, and 40% of these patients never experienced a relapse of symptoms 
until the medication was discontinued. During treatment, 30% of the patients 
experienced gastrointestinal disturbance, mainly diarrhea, which was easily controlled 
by dosage adjustments. Limitations to this study included the likelihood of a strong 
selection bias, considering the absence of randomization in both selection and 
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allocation. Also, no blinding was done in this study as was understood when patients 
were informed about the trail, medications and their side effects, therefore leaving a 
strong possibility of measurement bias. These limitations decrease the validity of this 
study. 
The last study reviewed was Lynde and Rogers III (2009). This observational 
study showed that 60% of the patient had therapeutic success with use of colchicine as 
monotherapy, and of these patients, 97% were said to have a substantial response in 
regard to frequency, intensity, and severity of RAS attacks. One patient experienced 
complete remission while using colchicine. No serious adverse effects were seen with 
the use of colchicine during the study and the most common side effect was diarrhea, 
occurring in 31% of the patients using colchicine. The study design was a retrospective 
review of medical records in patients with complex aphthosis, and as such, is likely 
limited by bias. The study was also limited in terms of the vagueness in response to 
therapy, which was evaluated subjectively and objectively by the patient and the 
physician. 
Using the Grading of Recommendations Assessment, Development and 
Evaluation (GRADE), each study was appraised to determine the quality of evidence 
and strength of recommendation. The first study, Pakfetrat et al. (2010), was the only 
randomized controlled trial used in this systematic review. As such, it was given a high 
grade initially and the limitations were reviewed. The study was double blinded and 
randomized with no serious limitations, inconsistencies, indirectness, imprecisions, or 
bias, and therefore, was not downgraded and remained a high quality of supporting 
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evidence (Appendix A, Table 1). As a result, the study shows strong evidence that 
colchicine is a safe and effective treatment for pain and relapse prevention of RAS. 
The two other studies reviewed, Mimura et al (2009) and Lynde and Rogers III 
(2009), were both observational studies. These two studies achieved all their desired 
outcomes of pain reductions and relapse prevention. Since the studies were 
observational, and neither were blinded or randomized, an initial low grade was 
determined using GRADE. Neither study met requirements to upgrade their quality as 
demonstrated in Appendix A, Table one. With all studies achieving the desired 
outcomes of this review, all were evaluated using GRADE and subsequently given an 
overall moderate GRADE of evidence as shown in Appendix A, Table 1. A moderate 
overall GRADE for the evidence in the literature reviewed suggests that further research 
is likely to have an impact on estimate of benefit and risk, which may or may not change 
the clinical effect.  
In summary, there is moderate evidence that supports the safety and efficacy of 
colchicine for the treatment of RAS. Colchicine proved to relieve pain and decrease 
relapse in the majority of patients in all three studies without the occurrence of severe 
adverse effects. A large prospective, double blind, randomized-controlled trial, with 
longer duration of treatment would likely benefit this proposition and further evaluate the 
superiority of colchicine in comparison to other systemic drugs for the treatment of RAS. 
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